Table 1.
Clinical characteristics of participants
| HIV-1 | HIV-2 | Seronegative | |||
|---|---|---|---|---|---|
| ART-naïve | ART- receivingd | ART-naïve | ART- receivingd | ||
| Number of participants | 24 | 19 | 16 | 19 | 33 |
| Agea (Years) | 39 (18–57) | 41.50 (30–50) | 46 (23–55) | 45.5 (20–59) | 30 (21–55) |
| CD4 Cell Counta (Cells/ul) | 554 (210–990) | 625 (372–1508) | 813b (504-1641) | 441c (158-1107) | NA |
| Viremiaa (RNA Copies/ml) | 14,199 (203–400,644) | < 34 | NA | NA | NA |
| Duration between diagnosis and samplinga (Years) | 1.4 (0.8–3.5) | 4 (2–6) | 1 (0.5–3) | 3 (1–7) | – |
aData are expressed as the median (range)
bAbsolute CD4 count for ART-naïve HIV-2 infected individuals was significantly higher than that for HIV-1 infected participants (unpaired t-test with Welch’s correction; p < 0.01)
cAbsolute CD4 count for ART-naïve HIV-2 infected individuals was significantly higher than that for ART-treated HIV-2 infected participants (unpaired t-test with Welch’s correction; p < 0.01)
NA not applicable
dART regimen for HIV-1 infected individuals was Zidovudine (AZT) + Lamivudine (3TC) + Nevirapine (NVP) and regimen for HIV-2 infected individuals was Zidovudine (AZT) + Lamivudine (3TC) + Lopinavir /Ritonavir (LPV)
All individuals that were included in ART receiving groups of either infection were on ART for at least 1 year. For HIV-1 infected individuals, range with median duration was (1–3) 1.8 years and for HIV-2 infected individuals, range with median duration was (1–3) 2 years